Atlas Energy Corp. (CANSF)
| Market Cap | 44.55M -37.8% |
| Revenue (ttm) | n/a |
| Net Income | -2.68M |
| EPS | -0.00 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,000 |
| Open | 0.0633 |
| Previous Close | 0.0621 |
| Day's Range | 0.0608 - 0.0670 |
| 52-Week Range | 0.0460 - 0.1523 |
| Beta | 4.71 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Atlas Energy
Atlas Energy Corp. operates as an international upstream royalty and streaming company. It focuses on the identification, acquisition, and management of upstream oil and gas royalty and streaming transactions. The company was formerly known as Willow Biosciences Inc. and changed its name to Atlas Energy Corp. in June 2025. Atlas Energy Corp. is headquartered in Calgary, Canada. [Read more]
News
Atlas Energy Corp Reports Second Quarter 2026 Financial Results
CALGARY, Alberta, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its financial and operating results for th...
Atlas Energy Corp. Announces Appointments to Subsidiary Board and Extension of TSXV Sandbox Exit Deadline
CALGARY, Alberta, June 22, 2026 (GLOBE NEWSWIRE) -- Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce that Patrick Drouin and Dion Degrand will ...
Atlas Energy Reports First Quarter 2026 Financial Results
CALGARY, Alberta, May 13, 2026 (GLOBE NEWSWIRE) -- Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its financial and operating results for the...
Atlas Energy Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Operations and Filing of Its 2025 AIF
CALGARY, Alberta, April 06, 2026 (GLOBE NEWSWIRE) -- Atlas Energy Corp. (“Atlas” or the “Company”) (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its financial and operating results for t...
ATLAS ENERGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
CALGARY, AB , Aug. 28, 2025 /PRNewswire/ - Atlas Energy Corp. (" Atlas " or the " Company ") (TSXV: ATLE), a TSXV Sandbox issuer, is pleased to announce its unaudited consolidated interim financial s...
ATLAS ENERGY STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF ANDY DUNCAN AS SENIOR EXECUTIVE
CALGARY, AB , Aug. 1, 2025 /PRNewswire/ - Atlas Energy Corp. ("Atlas" or the "Company") (TSXV: ATLE), a TSXV Sandbox Listing, is pleased to announce the appointment of Andy Duncan as a Senior Executiv...
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
CALGARY, AB , May 12, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), announces its unaudited consolidated interim financial statements and related ...
WILLOW BIOSCIENCES INC. ANNOUNCES COMPLETION OF SALE OF OPERATING SUBSIDIARY AND MANAGEMENT CHANGES
CALGARY, AB , April 30, 2025 /PRNewswire/ - Willow Biosciences Inc. (the "Company") (TSX: WLLW) (OTCQB: CANSF) announces the completion today of the sale (the "Transaction") of its wholly-owned operat...
WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS
SUNNYVALE, Calif. , April 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and s...
WILLOW BIOSCIENCES REPORTS 2024 FINANCIAL RESULTS AND UPDATE REGARDING SALE OF OPERATING SUBSIDIARY
SUNNYVALE, Calif. , March 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a biotechnology company focused on industrial manufacturing of ingredi...
WILLOW ANNOUNCES INITIATION OF STRATEGIC REVIEW PROCESS
SUNNYVALE, Calif. , Jan. 20, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial m...
WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Company reports record revenue of $1.7 million in Q3 Company announced a partnership in the high growth biopesticides sector that is expected to generate over $2 million in revenue in its first year C...
WILLOW BIOSCIENCES ANNOUNCES NEW PARTNERSHIP WITH A GLOBAL INGREDIENT MANUFACTURER TO ADVANCE DEVELOPMENT OF A HIGH VALUE INGREDIENT FROM ITS PORTFOLIO
SUNNYVALE, Calif. , Nov. 7, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial ma...
WILLOW ANNOUNCES A SECOND PROGRAM WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP AN ENZYME FOR MANUFACTURING A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
Rapid success of first program leads to second collaboration to develop optimized enzyme for large scale manufacturing process Enzyme development expected to enable commercial-scale production of the ...
WILLOW ANNOUNCES COMMERCIAL LICENSE AND ROYALTY AGREEMENT WITH KALSEC INC.
The agreement with Kalsec anticipates milestone payments for finalizing research and development work and a royalty stream for Willow upon commercialization SUNNYVALE, Calif. , Sept. 5, 2024 /PRNewswi...
WILLOW BIOSCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Company reports record revenue of $1.0 million, an increase of approximately 600% over the second quarter of 2023 Signed strategic partnership with leading pharmaceutical manufacturer, Laurus Labs, to...
WILLOW BIOSCIENCES ANNOUNCES NEW FUNDED BIOPESTICIDES RESEARCH AND DEVELOPMENT PARTNERSHIP AFTER SUCCESSFULLY COMPLETING FEASIBILITY STUDY
After a successful feasibility study, Company expands into the high growth biopesticide sector with a funded research and development program to produce valuable natural ingredients using its precisio...
WILLOW BIOSCIENCES PROVIDES CORPORATE UPDATE AND ANNOUNCES SIGNING OF A NEW PARTNERED PROGRAM
Company announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients Company anticipates revenue of over $1.0 million in Q2, and o...
WILLOW ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS FOR MANUFACTURING ACTIVE PHARMACEUTICAL INGREDIENTS
Collaboration provides Laurus access to Willow's AI-driven bioengineering platform The strategic alliance includes an initial seven high-value advanced intermediates and active pharmaceutical ingredie...
WILLOW BIOSCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Company continues to advance its corticosteroid production platform and anticipates signing a large strategic partnership in Q2 2024 Signed two new program agreements, and advanced three programs to t...
WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF
Completed the reorganization of the Company during 2023 with all lab operations now located in the Sunnyvale, California Record revenue in 2023 of $1.2 million representing 43% growth over 2022 Record...
WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC
CALGARY, AB , Feb. 29, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufac...
WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS
Investment further validates Willow's technology for the development and sustainable manufacture of natural ingredients Additional capital will accelerate commercialization of Willow's pipeline CALGAR...
WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
SUNNYVALE, Calif. , Jan. 31, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of p...
WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
SUNNYVALE, Calif., Jan. 16, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pu...